Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis

The first‐line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2‐targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or paclitaxel). The three‐drug regimen costs over $320,000 per treatment course, require...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Small (Weinheim an der Bergstrasse, Germany) Germany), 2022-03, Vol.18 (11), p.e2107550-n/a
Hauptverfasser:	Ngamcherdtrakul, Worapol, Bejan, Daniel S., Cruz‐Muñoz, William, Reda, Moataz, Zaidan, Husam Y., Siriwon, Natnaree, Marshall, Suphalak, Wang, Ruijie, Nelson, Molly A., Rehwaldt, Justin P. C., Gray, Joe W., Hynynen, Kullervo, Yantasee, Wassana
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies Antineoplastic Combined Chemotherapy Protocols - therapeutic use Brain Brain Neoplasms - drug therapy Breast cancer Breast Neoplasms - pathology Female Growth factors HER2 Humans Mice Nanoparticles Nanotechnology Receptor, ErbB-2 - genetics RNA, Small Interfering Side effects siRNAs taxane Taxanes Taxoids - pharmacology Taxoids - therapeutic use Trastuzumab - adverse effects Trastuzumab - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!